Associations between prior HPV4 vaccine doses and cervical cancer screening participation

Boone, Stephanie D.; Pinkston, Christina; Baumgartner, Kathy B.; Baumgartner, Richard N.; Harper, Sean M.; Bonham, Aaron J.; Paynter, Christopher A.; Harper, Diane M.

doi:10.1016/j.canep.2016.04.003

Cited by 14 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cervical cancer screening rates were similar to those seen in the US, at 86%, in fully vaccinated women, which is significantly higher than in unvaccinated women (75%) [69]. Likewise similar to the US population [63], the fully vaccinated women returned for the second round of screening significantly more often than the unvaccinated women.…”

Section: Hpv Vaccination Changes Subsequent Screening Patternssupporting

confidence: 70%

“…Most often the women participated in an initial screening within 15 days of their vaccination. Long term, though, continued screening compliance occurred significantly more often among those receiving three doses of vaccine; these highly compliant women were significantly more likely to participate in every 3 year screening over 7 years than those receiving fewer than three or no doses [63]. Nevertheless, participation in screening was dependent on the age at which women received vaccination.…”

Section: Hpv Vaccination Changes Subsequent Screening Patternsmentioning

confidence: 95%

“…In the US, a study of high risk, low income women showed that those who received, at any age, one dose of HPV vaccine were most likely to participate in screening at 21 years or older, significantly more than those receiving two, three or no doses [63]. Most often the women participated in an initial screening within 15 days of their vaccination.…”

Section: Hpv Vaccination Changes Subsequent Screening Patternsmentioning

confidence: 99%

See 2 more Smart Citations

HPV vaccines – A review of the first decade

Harper

DeMars

2017

Gynecologic Oncology

Self Cite

350

249

View full text Add to dashboard Cite

Pre-adolescent girls (9-15years) have the option of receiving a two dose HPV vaccine series at either a six month or one year interval to provide protection from HPV 16, the most prevalent type associated with cervical cancers, as well as several other less prevalent types. This series of vaccinations is highly likely to protect her from HPV infection until she enters the routine screening program, whether that be primary HPV testing or a combination of HPV testing and cytology. The two dose program has been recommended by the World Health Organization (WHO) since 2015. For women 15years and older, the three dose vaccine schedule is still recommended. The past ten years of Gardasil use has provided evidence of reduced HPV 16/18 infections in countries where there has been high coverage. Gardasil9 has replaced Gardasil. Gardasil9 has the same rapid anti-HPV 18 and HPV45 titer loss as Gardasil did. Cervarix remains equivalent to Gardasil9 in the prevention of HPV infections and precancers of any HPV type; Cervarix also has demonstrated sustained high antibody titers for at least 10years. One dose of Cervarix provides protection against HPV 16/18 infection with robust antibody titers well above natural infection titers. This may offer the easiest and most cost effective vaccination program over time, especially in low and lower middle income countries. Cervical cancer screening must continue to control cancer incidence over the upcoming decades. Future studies of prophylactic HPV vaccines, as defined by the WHO, must demonstrate protection against six month type specific persistent infections, not actual cervical cancer precursor disease endpoints, such as cervical intraepithelial neoplasia grade 3 (CIN 3) or adenocarcinoma in situ (AIS). This simplifies and makes less expensive future comparative studies between existing and new generic vaccines.

show abstract

Section: Hpv Vaccination Changes Subsequent Screening Patternssupporting

confidence: 70%

Section: Hpv Vaccination Changes Subsequent Screening Patternsmentioning

confidence: 95%

Section: Hpv Vaccination Changes Subsequent Screening Patternsmentioning

confidence: 99%

See 1 more Smart Citation

HPV vaccines – A review of the first decade

Harper

DeMars

2017

Gynecologic Oncology

Self Cite

350

249

View full text Add to dashboard Cite

show abstract

“…Our updated findings are consistent with findings from other countries of higher cervical screening participation among women who have been vaccinated against HPV …”

supporting

confidence: 92%

The value of data linkage depends on the quality of the data: incorporating Medicare data alters cervical screening analysis findings

Budd

Powierski

Chau

et al. 2020

Medical Journal of Australia

View full text Add to dashboard Cite

show abstract

“…There also is a need for ongoing research regarding women's knowledge and beliefs about screening, particularly given the potential for future changes in screening guidelines to HPV DNA testing only, such as those being implemented in 2017 in Australia and 2018 in New Zealand (Smith et al, 2016, Lew et al, 2016). One recent study examining a largely minority population did also find positive associations between HPV vaccination and cervical cancer screening (Boone et al, 2016). However, these results, obtained from medical records, were not able to examine women's knowledge and beliefs regarding vaccination and screening in order to illuminate the relationship between the two.…”

Section: Introductionmentioning

confidence: 99%

Differences in cervical cancer screening knowledge, practices, and beliefs: An examination of survey responses

Kasting

Wilson

Zollinger

et al. 2017

Preventive Medicine Reports

View full text Add to dashboard Cite

Among the identified barriers to HPV vaccination is the concern that women may compensate for their reduced susceptibility to cervical cancers by reducing cervical cancer screening. This exploratory study examined the relationship between cervical cancer screening rates and HPV vaccination. We conducted a cross-sectional survey using a convenience sample of women aged 21–35 attending a local minority health fair in July 2015. Data were analyzed in 2015–2016. Outcomes assessed were: receiving a Pap test within the last three years, awareness and comfort with current Pap test recommendations, and knowledge regarding the purpose of a Pap test. A total of 291 women were included in the analyses. Mean age was 28.5 years and 62% were non-Hispanic black. 84% had received a Pap test in the last three years and 33% had received at least one HPV vaccine. Logistic regression results showed that women who had been vaccinated did not have lower odds of having a Pap test in the past three years (OR = 1.32; 95% CI = 0.66–2.65). In an adjusted regression model controlling for age and race, vaccinated women were significantly more likely to have had a Pap test (AOR = 3.06; 95% CI = 1.37–6.83). Yet only 26% of women knew the purpose of a Pap test and the proportion who answered correctly was higher among non-Hispanic white women. Women who have been vaccinated for HPV are more likely to have been screened for cervical cancer. These results suggest areas for more robust studies examining pro-health attitudes, behaviors, and communication regarding vaccination and preventive screening.

show abstract

Associations between prior HPV4 vaccine doses and cervical cancer screening participation

Cited by 14 publications

References 34 publications

HPV vaccines – A review of the first decade

HPV vaccines – A review of the first decade

The value of data linkage depends on the quality of the data: incorporating Medicare data alters cervical screening analysis findings

Differences in cervical cancer screening knowledge, practices, and beliefs: An examination of survey responses

Contact Info

Product

Resources

About